Abstract

Glucocorticoid (GC) induced osteoporosis (GIO) is caused by the long-term use of GC for treatment of autoimmune and inflammatory diseases. The GC related disruption of bone marrow microcirculation and increased adipogenesis contribute to GIO development. However, neither currently available anti-osteoporosis agent is completely addressed to microcirculation and bone marrow adipogenesis. Salvianolic acid B (Sal B) is a polyphenolic compound from a Chinese herbal medicine, Salvia miltiorrhiza Bunge. The aim of this study was to determine the effects of Sal B on osteoblast bone formation, angiogenesis and adipogenesis-associated GIO by performing marrow adipogenesis and microcirculation dilation and bone histomorphometry analyses. (1) In vivo study: Bone loss in GC treated rats was confirmed by significantly decreased BMD, bone strength, cancellous bone mass and architecture, osteoblast distribution, bone formation, marrow microvessel density and diameter along with down-regulation of marrow BMPs expression and increased adipogenesis. Daily treatment with Sal B (40 mg/kg/d) for 12 weeks in GC male rats prevented GC-induced cancellous bone loss and increased adipogenesis while increasing cancellous bone formation rate with improved local microcirculation by capillary dilation. Treatment with Sal B at a higher dose (80 mg/kg/d) not only prevented GC-induced osteopenia, but also increased cancellous bone mass and thickness, associated with increase of marrow BMPs expression, inhibited adipogenesis and further increased microvessel diameters. (2) In vitro study: In concentration from 10−6 mol/L to 10−7 mol/L, Sal B stimulated bone marrow stromal cell (MSC) differentiation to osteoblast and increased osteoblast activities, decreased GC associated adipogenic differentiation by down-regulation of PPARγ mRNA expression, increased Runx2 mRNA expression without osteoblast inducement, and, furthermore, Sal B decreased Dickkopf-1 and increased β-catenin mRNA expression with or without adipocyte inducement in MSC. We conclude that Sal B prevented bone loss in GC-treated rats through stimulation of osteogenesis, bone marrow angiogenesis and inhibition of adipogenesis.

Highlights

  • Glucocorticoid (GC) therapy is commonly used for inflammatory and autoimmune diseases

  • Compared with the 6 month old rat, the aging associated changes seen at 9 months included significantly increased femoral cortical bone strength parameters, decreased proximal tibial (PT) longitudinal growth rate (LGR), decreased proximal tibial metaphyses (PTM) cancellous bone formation (i.e. MS/bone surface (BS), bone formation rate (BFR)/BS, BFR/ bone volume (BV), BFR/tissue volume (TV) down by 25, 28, 26 and 44%) and endocortical bone formation indices (i.e. Ec-MS/BS, endocortical mineral apposition rate (Ec-MAR) and endocortical bone formation rate (Ec-BFR)/ BS by 26, 49 and 62%), these changes were associated with significantly increased distal femoral marrow microvessels diameter (DMV), up by 54%

  • Compared to the vehicle control, the 40 mg of Salvianolic acid B (Sal B)/kg/d (Sal B40) treated intact male rat showed no significant changes on body and soft tissues weights, bone mineral density (BMD), femoral cortical bone strength, proximal tibial metaphysis (PTM) cancellous bone mass, architecture and endocortical bone formation

Read more

Summary

Introduction

Glucocorticoid (GC) therapy is commonly used for inflammatory and autoimmune diseases. The clinical management of GIO relies on medications similar to those used for treatment of post-menopausal osteoporosis, such as calcium, vitamin D, bisphosphonates, raloxifene, PTH, hormone replacement and calcitonin. These drugs do not address the multi-factor driven GIO. They do not target the detrimental effect of GC on bone marrow fat metabolism and circulatory system [2,3,4,5].

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call